OP
VKTX icon

ORG Partners’s Viking Therapeutics VKTX Stock Holding History

ORG Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$5.03K Buy
143
+33
+30% +$1.17K ﹤0.01% 1220
2025
Q3 		$2.89K Buy
110
+60
+120% +$1.79K ﹤0.01% 1249
2025
Q2 		$1.33K Hold
50
– – ﹤0.01% 1295
2025
Q1 		$1.2K Sell
50
-150
-75% -$4.74K ﹤0.01% 1147
2024
Q4 		$8.05K Buy
+200
New +$11.4K ﹤0.01% 939
2024
Q3 		– Sell
-4,429
Closed -$245K – 1378
2024
Q2 		$245K Buy
+4,429
New +$290K 0.03% 384

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ORG Partners's VKTX Position: Q4 2025 in Review

ORG Partners increased its Viking Therapeutics (VKTX) stake by 30% in Q4 2025, buying an estimated $1.17K and bringing the position to 143 shares worth $5.03K. The position accounts for ﹤0.01% of the portfolio, ranked #1220.

ORG Partners first reported a position in VKTX in Q2 2024 and has held it in 6 quarters since. The position peaked at $245K in Q2 2024. 426 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • ORG Partners held 143 shares of Viking Therapeutics worth $5.03K as of Q4 2025.
  • ORG Partners bought 33 Viking Therapeutics shares in Q4 2025, an estimated $1.17K.
  • Viking Therapeutics made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1220 holding.
  • ORG Partners first reported a position in Viking Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • ORG Partners's Viking Therapeutics position peaked at $245K in Q2 2024.
  • 426 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.